Trazodone for the treatment of fibromyalgia: an open-label, 12-week study

Piedad Morillas-Arques, Carmen Ma Rodriguez-Lopez, Rocio Molina-Barea, Fernando Rico-Villademoros, Elena P Calandre, Piedad Morillas-Arques, Carmen Ma Rodriguez-Lopez, Rocio Molina-Barea, Fernando Rico-Villademoros, Elena P Calandre

Abstract

Background: Despite its frequent use as a hypnotic, trazodone has not been systematically assessed in fibromyalgia patients. In the present study have we evaluated the potential effectiveness and tolerability of trazodone in the treatment of fibromyalgia.

Methods: A flexible dose of trazodone (50-300 mg/day), was administered to 66 fibromyalgia patients for 12 weeks. The primary outcome measure was the Pittsburgh Sleep Quality Index (PSQI). Secondary outcome measures included the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depression Inventory (BDI), the Hospital Anxiety and Depression Scale (HADS), the Brief Pain Inventory (BPI), the Short-Form Health Survey (SF-36), and the Patients' Global Improvement Scale (PGI). Trazodone's emergent adverse reactions were recorded. Data were analyzed with repeated measures one-way ANOVA and paired Student's t test.

Results: Trazodone markedly improved sleep quality, with large effect sizes in total PSQI score as well on sleep quality, sleep duration and sleep efficiency. Significant improvement, although with moderate effect sizes, were also observed in total FIQ scores, anxiety and depression scores (both HADS and BDI), and pain interference with daily activities. Unexpectedly, the most frequent and severe side effect associated with trazodone in our sample was tachycardia, which was reported by 14 (21.2%) patients.

Conclusions: In doses higher than those usually prescribed as hypnotic, the utility of trazodone in fibromyalgia management surpasses its hypnotic activity. However, the emergence of tachycardia should be closely monitored.

Trial registration: This trial has been registered with ClinicalTrials.gov number NCT-00791739.

Trial registration: ClinicalTrials.gov NCT00791739.

Figures

Figure 1
Figure 1
Patients flow diagram.

References

    1. Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, trand CV, Williams DA. OMERACT Fibromyalgia Working Group. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009;36:2318–2329. doi: 10.3899/jrheum.090367.
    1. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;46:469–476. doi: 10.4088/JCP.v66n0409.
    1. Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Artzeni F. Treatment strategy in fibromyalgia syndrome: where are we now? Semin Arthritis Rheum. 2008;37:353–365. doi: 10.1016/j.semarthrit.2007.08.008.
    1. American Pain Society. Guideline for the management of fibromyalgia syndrome pain in adults and children (complete summary) National Guideline Clearinghouse. accessed April 2010.
    1. Branco JC, Martini A, Paiva T. Treatment of sleep abnormalities and clinical complaints in fibromyalgia with trazodone. Arthritis Rheum. 1996;39:S91.
    1. Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry. 1990;51(Suppl 9):18–22.
    1. Yamadera H, Suzuki H, Nakamura S, Endo S. Effects of trazodone on polysomnography, blood concentration and core body temperature in healthy volunteers. Psychiatry Clin Neurosci. 1999;53:189–191. doi: 10.1046/j.1440-1819.1999.00531.x.
    1. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectrums. 2009;14:536–546.
    1. Erman MK. Therapeutic options in the treatment of insomnia. J Clin Psychiatry. 2005;66(Suppl 9):18–23.
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardieri C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Farber SJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160–172. doi: 10.1002/art.1780330203.
    1. Trazodone package insert. accessed April 2010.
    1. Royuela A, Macías JA. Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño. 1997;9:81–94.
    1. Rivera J, González T. The Fibromyalgia Impact Questionnaire: A validated spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol. 2004;22:554–460.
    1. Vazquez C, Sanz J. Fiabilidad y valores normales de la versión española del inventario para la depresión de Beck de 1978. Clin Salud. 1997;8:403–422.
    1. Quintana JM, Padierna A, Esteban C, Arostegui I, Bilbao A, Ruiz I. Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 2003;107:216–221. doi: 10.1034/j.1600-0447.2003.00062.x.
    1. Badia X, Muriel C, Gracia A, Núñez-Olarte JM, Perulero N, Galvez R, Carulla J, Cleeland CS. Grupo Vesbpi. Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica. Med Clin (Barc) 2003;120:52. doi: 10.1157/13042265.
    1. Alonso J, Prieto L, Antó JM. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 1995;104:771–776.
    1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz D, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40. doi: 10.1176/appi.ajp.163.1.28.
    1. Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs. A review. Psychopharmacology. 1996;126:1–16. doi: 10.1007/BF02246405.
    1. Saletu B, Prause W, Anderer P, Mandl M, Aigner M, Mikova O, Saletu-Zyhlarz GM. Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the Somnolyzer 24 × 7 and the Siesta database. Neuropsychobiology. 2005;51:148–163. doi: 10.1159/000085207.
    1. Branco J, Atalaia A, Paiva T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J Rheumatol. 1994;21:1113–1117.
    1. Wolfe F, Claw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–610. doi: 10.1002/acr.20140.
    1. Clayton AH, West SG. Combination therapy for fibromyalgia. Curr Pharm Design. 2006;12:11–16. doi: 10.2174/138161206775193163.
    1. Hughes G, Martinez C, Myon E, Taïeb C, Wessely S. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK. An observational study based on clinical practice. Arthritis Rheum. 2006;54:177–183. doi: 10.1002/art.21545.
    1. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997;40:1560–1570. doi: 10.1002/art.1780400904.
    1. White KP, Nielson WR, Harth M, Ostbye T, Speechley M. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002;47:260–265. doi: 10.1002/art.10400.
    1. Horne JA, Percival JE, Traynor JR. Aspirin and human sleep. Electroencephalogr Clin Neurophysiol. 1980;49:409–413. doi: 10.1016/0013-4694(80)90238-2.
    1. Walder B, Tramèr MR, Blois R. The effects of two single doses of tramadol on sleep: a randomized, cross-over trial in healthy volunteers. Eur J Anaesthesiol. 2001;18:36–42.
    1. Gengo F. Effects of ibuprofen on sleep quality as measured using polysomnography and subjective measures in healthy adults. Clin Ther. 2006;28:1820–1826. doi: 10.1016/j.clinthera.2006.11.018.
    1. Chalon S, Pereira A, Lainey E, Vanderhende F, Watkin JG, Staner L, Granier LA. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology. 2005;177:357–365. doi: 10.1007/s00213-004-1961-0.
    1. Haria M, Fitton A, McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression, and therapeutic potential in other disorders. Drugs Aging. 1994;4:331–355. doi: 10.2165/00002512-199404040-00006.
    1. Martinez-Lavin M, Vargas A. Complex adaptive systems allostasis in fibromyalgia. Rheum Clin Dis North Am. 2009;35:285–298. doi: 10.1016/j.rdc.2009.05.005.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj